Financing Quarterly Statistics, Q2 2020
A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, April-June 2020
During Q2 biopharmas brought in an aggregate $32.3bn in financings and device company fundraising totaled $9.5bn; while in vitro diagnostic firms and research tools players brought in $2bn across the period.
You may also be interested in...
Company specializing in trading upfront cash for downstream earnings makes its public debut with largest IPO of 2020, and the second largest ever in biopharma.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Ten $1bn+ alliances were penned in January. In the top alliance by deal value, Shanghai Argo Biopharmaceutical entered into exclusive collaboration with Novartis Pharma for two undisclosed Argo cardiovascular disease programs, one in Phase I and another in Phase I/IIa. Novartis gets an exclusive global license to develop and commercialize the Phase I program and also receives an option to potentially license compounds directed against up to two additional targets. For the Phase I/IIa program, Novartis gets an exclusive license worldwide except in Greater China. The deal could be worth up to $4.17bn for Argo.